首页> 外文期刊>Retina >SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY
【24h】

SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY

机译:玻璃体内注射治疗术后的短期成果与ranibizumab治疗早熟的视网膜病变

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: Intravitreal injection of conbercept (IVC) is the latest applied treatment that could be used in retinopathy of prematurity (ROP) patients. The structural outcomes and recurrence of ROP among patients treated with IVC or intravitreal injection of ranibizumab (IVR) were compared.
机译:目的:玻璃体内注射Conbercept(IVC)是最新的应用处理,可用于早产儿(ROP)患者的视网膜病变。 比较了用IVC或玻璃体硝基脲注射术治疗RANIBizumab(IVR)的患者ROP的结构性结果和复发。

著录项

  • 来源
    《Retina》 |2018年第8期|共10页
  • 作者单位

    Peking Univ Peoples Hosp Beijing Key Lab Diag &

    Therapy Retinal &

    Choroida Dept Ophthalmol;

    Peking Univ Peoples Hosp Beijing Key Lab Diag &

    Therapy Retinal &

    Choroida Dept Ophthalmol;

    Peking Univ Peoples Hosp Beijing Key Lab Diag &

    Therapy Retinal &

    Choroida Dept Ophthalmol;

    Peking Univ Peoples Hosp Beijing Key Lab Diag &

    Therapy Retinal &

    Choroida Dept Ophthalmol;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 眼科学;
  • 关键词

    conbercept; intravitreal injection; ranibizumab; retinopathy of prematurity;

    机译:Conbercept;玻璃体内注射;Ranibizumab;早产的视网膜病变;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号